(2S,4R)-4-羟基哌啶-2-羧酸甲酯盐酸盐 | 175671-43-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S,4R)-4-羟基哌啶-2-羧酸甲酯盐酸盐
• 中文别名: (2S,4R)-甲基4-羟基哌啶-2-羧酸盐酸盐
• 英文名称: (2S,4R)-methyl 4-hydroxypiperidine-2-carboxylate hydrochloride
• 英文别名: methyl 4(R)-hydroxypiperidine-2(S)-carboxylate hydrochloride；methyl (2S,4R)-4-hydroxypiperidine-2-carboxylate;hydrochloride
• CAS: 175671-43-9
• 化学式: C₇H₁₃NO₃*ClH
• 分子量: 195.646
• InChiKey: ZZQYALUPYHIFSA-IBTYICNHSA-N

物化性质

• 熔点：
  173-176℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.31
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,4R)-4-羟基哌啶-2-羧酸甲酯盐酸盐 在 盐酸 作用下， 生成 (2S,4r)-顺式-4-羟基哌啶-2-羧酸
  参考文献：
  名称：

  Preparation of (2S,4R)-4-Hydroxypipecolic Acid and Derivatives

  摘要：

  DOI：

  10.1021/jo9519874
• 作为产物：
  描述：

  (2S,4R)-4-羟基-2-哌啶羧酸甲酯 在 盐酸 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 以90%的产率得到(2S,4R)-4-羟基哌啶-2-羧酸甲酯盐酸盐
  参考文献：
  名称：

  Validation of high-affinity binding sites for succinic acid through distinguishable binding of gamma-hydroxybutyric acid receptor-specific NCS 382 antipodes

  摘要：

  Gamma-hydroxybutyric acid (GHB) binding to multiple sites for the tricarboxylic acid cycle intermediate succinic acid (SUC) has been disclosed recently. In order to better characterize these targets, distinguishable binding of GHB receptor-specific NCS 382 antipodes to [H-3]-SUC or [H-3]-GHB labelled sites in rat brain synaptic membranes was explored. Eutomer binding parameters suggest identity of the high-affinity target for SUC with a synaptic GHB receptor subtype. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.083

文献信息

• Novel diazepan derivatives
  申请人：Aebi Johannes

  公开号：US20070249589A1

  公开（公告）日：2007-10-25

  The invention is concerned with novel diazepan derivatives of formula (I) wherein A, X, R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

  这项发明涉及式（I）的新型二氮杂环己烷衍生物，其中A、X、R3、R4、R5、R6、R8、R9、R10、R11、R12、R13、m和n的定义如描述和索赔中所述，以及其生理上可接受的盐。这些化合物是CCR-2受体、CCR-5受体和/或CCR-3受体的拮抗剂，可用作药物。
• [EN] G-A CROSSLINKING CYTOTOXIC AGENTS<br/>[FR] AGENTS CYTOTOXIQUES DE RÉTICULATION G-A
  申请人：FEMTOGENIX LTD

  公开号：WO2020157491A1

  公开（公告）日：2020-08-06

  The invention relates to a compound of formula (I): or salts, solvates, isomers or tautomers thereof, wherein; A is a group selected from: R1 is selected from H and halogen; either R2 is selected from -CH2-halogen, C1-6 alkyl and H, and R3 is H or is absent; or R2 and R3 together with the carbon atoms to which they are attached form a cyclopropyl ring; SP is a spacer group; B is a polycyclic group: R11, R12, R13 and R14 are selected such that either: (aa) one of R11, R12, R13 and R14 is E and another of R11, R12, R13 and R14 is an optionally substituted Ar1 group; or (ab) one of R11, R12, R13 and R14 is Rx, wherein Rx is Ar1-Z1-E or -E1-Z1-Ar1; and Ar1 is an optionally substituted C5-20 aryl or C5-10 heteroaryl groupeach E is independently selected from (CH2)j-S(0)2-NR25R26, (CH2)j-S(0)2-0H, CH2CH2[0CH2CH2]WR25 and E1; and Z1 is NR26, C(=0)-0, O or is absent and these compounds are useful as medicaments, in particular as anti-proliferative agents.

  该发明涉及一种化合物，其化学式为(I)：或其盐、溶剂合物、异构体或互变异构体，其中；A是从中选择的一个基团：R1从H和卤素中选择；R2从-CH2-卤素、C1-6烷基和H中选择，R3是H或不存在；或者R2和R3与它们连接的碳原子一起形成环丙基环；SP是一个间隔基团；B是一个多环基团：R11、R12、R13和R14被选择为：(aa) R11、R12、R13和R14中的一个是E，另一个是可选择取代的Ar1基团；或者(ab) R11、R12、R13和R14中的一个是Rx，其中Rx是Ar1-Z1-E或-E1-Z1-Ar1；Ar1是可选择取代的C5-20芳基或C5-10杂环芳基，每个E独立选择自( )j-S(0)2-NR25R26、( )j-S(0)2-0H、 [0 ]WR25和E1；Z1是NR26、C(=0)-0、O或不存在，这些化合物可用作药物，特别是作为抗增殖剂。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2016142867A1

  公开（公告）日：2016-09-15

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及对抗血管紧张素II型2(AT2)受体的杂环化合物。更具体地，本发明涉及公式(I)所述的化合物，包含它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病中的使用，包括神经病理性疼痛、炎症性疼痛、与神经元过敏性相关的疾病、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成不平衡相关的疾病以及与异常神经再生相关的疾病。
• Heterocyclic compounds and methods for their use
  申请人：NOVARTIS AG

  公开号：US10308628B2

  公开（公告）日：2019-06-04

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及可用于拮抗血管紧张素 II 2 型（AT2）受体的杂环化合物。更具体地说，本发明涉及本文所述的式(I)化合物、含有它们的组合物及其在治疗或预防与AT2受体功能有关的紊乱或疾病的方法中的用途，这些紊乱或疾病包括神经性疼痛、炎症性疼痛、与神经元超敏性有关的病症、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成失衡有关的紊乱以及与神经再生异常有关的紊乱。
• DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2010506A1

  公开（公告）日：2009-01-07